NDA 210557 · Cosette
Vyleesi (Autoinjector)
Bremelanotide Acetate · Subcutaneous
NovelLast checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jun 21, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
3 Phase 3, 0 recruiting
FAERS reports
1,150
35 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2026.
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. Limitations of Use VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance. VYLEESI is a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance ( 1 ). Limitations of Use ( 1 ): Not indicated for treatment of HSDD in postmenopausal women or in men. Not indicated to enhance sexual performance.
Mechanism: Bremelanotide is a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. At therapeutic dose levels, binding to MC1R and MC4R is most relevant. Neurons expressing MC4R are present in many areas of the central nervous system (CNS). The mechanism by which VYLEESI improves HSDD in women is unknown. The MC1R is expressed on melanocytes; binding at this receptor leads to melanin expression and increased pigmentation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VYLEESI (AUTOINJECTOR) · BREMELANOTIDE ACETATE EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bremelanotide" as an intervention, any sponsor and status, largest first.
- 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Palatin Technologies, IncIndustry
NCT02333071 · 723 participants · Start Dec 2014 · Primary completion Jul 2016
Drug: Bremelanotide · For: Hypoactive Sexual Desire Disorder
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 91 sites in all
- 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Palatin Technologies, IncIndustry
NCT02338960 · 714 participants · Start Jan 2015 · Primary completion Aug 2016
Drug: Bremelanotide; Placebo · For: Hypoactive Sexual Desire Disorder
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 91 sites in all
- Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Palatin Technologies, IncIndustry
NCT01382719 · 612 participants · Start Jun 2011 · Primary completion Sep 2012
Drug: bremelanotide · For: Female Sexual Arousal Disorder; Hypoactive Sexual Desire Disorder
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 68 sites in all
- Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT03973047 · 228 participants · Start Jun 17, 2019 · Primary completion Jul 19, 2019
Drug: Bremelanotide; Zofran and 1 more · For: Nausea
Sites: San Antonio, Texas
Kwang Dong Pharmaceutical co., ltd.Industry
NCT04943068 · 193 participants · Start May 10, 2021 · Primary completion May 16, 2023
Drug: Bremelanotide; Placebo · For: Hypoactive Sexual Desire Disorder
Sites: Seoul, South Korea
- A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityPivotal-lookingActive, not recruiting
Palatin Technologies, IncIndustry
NCT06565611 · 108 participants (planned) · Start Aug 5, 2024 · Primary completion Feb 5, 2025
Drug: bremelanotide; tirzepatide · For: Obesity
Sites: DeLand, Florida; Oklahoma City, Oklahoma; North Charleston, South Carolina · 4 sites in all
Imperial College Healthcare NHS TrustAcademic, hospital or other
NCT04179734 · 40 participants · Start Oct 7, 2019 · Primary completion Oct 6, 2020
Drug: Bremelanotide; Placebo · For: Hypoactive Sexual Desire Disorder
Sites: London, United Kingdom
- A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseCompleted
Palatin Technologies, IncIndustry
NCT05709444 · 16 participants · Start Dec 26, 2022 · Primary completion Apr 26, 2024
Drug: Bremelanotide; RAAS inhibition therapy · For: Kidney Disease
Sites: Chula Vista, California; La Mesa, California; Decatur, Georgia · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea494
- drug ineffective237
- headache170
- vomiting127
- off label use122
- illness88
- flushing83
- adverse drug reaction65
- dizziness51
- feeling abnormal50
- fatigue48
- malaise43
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 40 |
| 2020 | 50 |
| 2021 | 18 |
| 2022 | 45 |
| 2023 | 150 |
| 2024 | 155 |
| 2025 | 341 |
| 2026 | 351 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D, Lynch SE · Ann Pharmacother 2020 · Systematic Review
- Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH, Althof SE, Kingsberg S, et al. · Womens Health (Lond) 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Spielmans GI · J Sex Res 2021 · Meta-Analysis
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Toledo RG, Winkelman WD, Reyes-Gonzalez D, et al. · J Minim Invasive Gynecol 2026 · Systematic Review, Meta-Analysis
- Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.
Weinberger JM, Houman J, Caron AT, et al. · Obstet Gynecol 2018 · Meta-Analysis
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Clayton AH, Kingsberg SA, Portman D, et al. · J Womens Health (Larchmt) 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.